129 related articles for article (PubMed ID: 2495219)
1. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.
Olofsson BO; Dahlén G; Nilsson TK
Eur Heart J; 1989 Jan; 10(1):77-82. PubMed ID: 2495219
[TBL] [Abstract][Full Text] [Related]
2. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations].
Rabijewski M; Zgliczyński W
Endokrynol Pol; 2007; 58(3):213-9. PubMed ID: 17940987
[TBL] [Abstract][Full Text] [Related]
3. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
Akanji AO; Abdullah A; Tahzeeb S
Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis.
Segarra A; Chacón P; Martinez-Eyarre C; Argelaguer X; Vila J; Ruiz P; Fort J; Bartolomé J; Camps J; Moliner E; Pelegrí A; Marco F; Olmos A; Piera L
J Am Soc Nephrol; 2001 Jun; 12(6):1255-1263. PubMed ID: 11373350
[TBL] [Abstract][Full Text] [Related]
6. Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
Deepa R; Velmurugan K; Saravanan G; Dwarakanath V; Agarwal S; Mohan V
J Assoc Physicians India; 2002 Jul; 50():901-6. PubMed ID: 12126344
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease.
Oseroff A; Krishnamurti C; Hassett A; Tang D; Alving B
J Lab Clin Med; 1989 Jan; 113(1):88-93. PubMed ID: 2783330
[TBL] [Abstract][Full Text] [Related]
8. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients.
Warshofsky MK; Wasserman HS; Wang W; Teng P; Sciacca R; Apfelbaum M; Schwartz A; Michler RE; Mancini DM; Cannon PJ; Rabbani LE
Am J Cardiol; 1997 Jul; 80(2):145-9. PubMed ID: 9230149
[TBL] [Abstract][Full Text] [Related]
10. Acute psychological stress decreases plasma tissue plasminogen activator (tPA) and tissue plasminogen activator/plasminogen activator inhibitor-1 (tPA/PAI-1) complexes in cardiac patients.
Hevey D; McGee HM; Fitzgerald D; Horgan JH
Eur J Appl Physiol; 2000 Nov; 83(4 -5):344-8. PubMed ID: 11138573
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up.
Jansson JH; Olofsson BO; Nilsson TK
Circulation; 1993 Nov; 88(5 Pt 1):2030-4. PubMed ID: 8222095
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor activity as a possible indicator of disease activity in rest angina with angiographically insignificant coronary artery stenosis.
Sakata K; Kurata C; Kobayashi A; Rydzewski A; Yamazaki N
Thromb Res; 1991 Sep; 63(5):491-502. PubMed ID: 1755002
[TBL] [Abstract][Full Text] [Related]
13. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
Hamsten A; Syvänne M; Silveira A; Luong LA; Nieminen MS; Humphries S; Frick MH; Taskinen MR
Thromb Haemost; 2000 Mar; 83(3):397-403. PubMed ID: 10744143
[TBL] [Abstract][Full Text] [Related]
15. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population.
Sundell IB; Nilsson TK; Hallmans G; Hellsten G; Dahlén GH
Atherosclerosis; 1989 Nov; 80(1):9-16. PubMed ID: 2532510
[TBL] [Abstract][Full Text] [Related]
16. Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease.
Caputo M; Mantini G; Floriani I; Ciceri M; Noseda A; Bonomo L
Eur Heart J; 1996 Sep; 17(9):1329-36. PubMed ID: 8880017
[TBL] [Abstract][Full Text] [Related]
17. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.
Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A
Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039
[TBL] [Abstract][Full Text] [Related]
18. Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross-sectional study in Norsjö, Sweden.
Hellsten G; Boman K; Bjerle P; Blom P; Nilsson TK
Eur Heart J; 1992 Jan; 13(1):57-60. PubMed ID: 1577032
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of fibrinolytic factors in coronary heart disease.
Wiman B
Scand J Clin Lab Invest Suppl; 1999; 230():23-31. PubMed ID: 10389198
[TBL] [Abstract][Full Text] [Related]
20. Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake.
Mehta J; Lawson D; Saldeen TJ
Am Heart J; 1988 Nov; 116(5 Pt 1):1201-6. PubMed ID: 3142242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
